The 5′ AMP-activated protein kinase (AMPK) is an energy sensor that is activated upon phosphorylation of Thr 172 in its activation loop by the kinase LKB1, CAMKK2, or TAK1. TAK1-dependent AMPK phosphorylation of Thr 172 is less well characterized than phosphorylation of this site by LKB1 or CAMKK2. An important target of TAK1 is IB kinase (IKK), which controls the activation of the transcription factor NF-B. We tested the hypothesis that IKK acted downstream of TAK1 to activate AMPK by phosphorylating Thr 
INTRODUCTION
AMPK [5′ adenosine monophosphate (AMP)-activated protein kinase] is a master energy-sensing kinase that phosphorylates various substrates to promote adenosine triphospate (ATP) conservation (1, 2) . AMPK appears to play a dual role in cancer depending on the context. AMPK can promote redox balance and mitophagy to favor tumor survival under metabolic stress, as is frequently observed in tumors. However, AMPK can inhibit growth signaling and protein synthesis pathways [notably mechanistic target of rapamycin (mTOR) signaling] to limit tumor growth (3) . AMPK activity is regulated by phosphorylation of Thr 172 in the kinase domain activation loop and allosterically by adenosine nucleotide binding (4) (5) (6) . Binding of AMP to the AMPK subunit induces an increase in AMPK activity, and binding of either AMP or adenosine diphosphate (ADP) promotes Thr 172 phosphorylation in the kinase domain by causing a conformational change in the AMPK holoenzyme that prevents phosphatases from accessing Thr 172 (5, 6) . In cell-free kinase assays, allosteric binding of AMP to the AMPK subunit causes a 5-fold increase in AMPK activity, whereas phospho rylation of Thr 172 causes a 100-fold increase in AMPK activity; thus, Thr 172 phosphorylation is the major point of AMPK regulation (4, (7) (8) (9) . Three kinases phosphorylate AMPK at Thr 172 : LKB1 (liver kinase B1), CAMKK2 (calcium/calmodulindependent protein kinase kinase 2), and TAK1 (transforming growth factor -activated kinase 1) (2). The kinase upstream of AMPK depends on the signaling cascade or specific stressor. When the AMP/ ATP ratio is increased in cells, a conformational shift occurs that makes Thr 172 more amenable to phosphorylation by LKB1 (10) (11) (12) . However, LKB1 is a tumor suppressor that is lost in many cancers, and these cancers still require AMPK for growth and survival (3), implying that other sources of AMPK activation are important in cancer. Stimuli such as ionomycin that lead to an increased concentration of intracellular calcium cause CAMKK2 to phosphorylate Thr 172 (13) (14) (15) .
In addition, cytokines such as interleukin-1 (IL-1), tumor necrosis factor (TNF), and TNF-related apoptosis-inducing ligand (TRAIL) lead to AMPK Thr 172 phosphorylation in a TAK1-dependent manner (16, 17) , although less is known about the mechanism by which TAK1 promotes AMPK Thr 172 phosphorylation. TAK1 is activated by inflammatory signals such as IL-1 and TNF and in turn activates several downstream pathways including the nuclear factor B (NF-B) transcription factor pathway, the c-Jun N-terminal kinase (JNK) pathway, the p38 pathway, and AMPK (18) . To activate p38 and JNK pathways, TAK1 phosphorylates mitogen-activated protein kinases (MAPKs). To activate the NF-B pathway, TAK1 directly phosphorylates IB kinase (IKK) to promote its activity. TAK1 promotes NF-B-dependent transcription by directly phosphorylating IKK at Ser 177 and Ser
181
, which lie within the IKK activation loop (19) . The canonical IKK complex consists of two highly related kinases (IKK and IKK) (20, 21) and a scaffolding protein [IKK; also known as NF-B essential modulator (NEMO)] (22, 23) . In addition to activation by TAK1, IKK can also be activated by trans-autophosphorylation especially in the presence of linear ubiquitin molecules (24) . IKK was originally described as the kinase responsible for the inducible phosphorylation of IB (25) . Phosphorylation of IB by IKK leads to its rapid proteasomemediated degradation, which in turn allows NF-B transcription factors to enter the nucleus and promote transcription. Although IKK is best known for its role in promoting the NF-B transcription activation pathway, NF-B-independent roles for IKK have been described (26) . The exact mechanisms that lead IKK to phosphorylate one substrate over another are incompletely understood, but it likely involves NEMO, which can act as a substrate specificity factor (22) . IKK promotes AMPK-dependent autophagy in an NF-B-independent manner (22, 27, 28 The mitochondrial complex I inhibitor phenformin causes energetic stress by rapidly depleting ATP (29) , leading to activation of AMPK in an LKB1-dependent manner and, consequently, energy conservation and growth arrest. Cells that lack LKB1 undergo apoptosis in response to phenformin treatment, which led to the notion that phenformin could be used therapeutically to treat LKB1-deficient cancers (29, 30) . Because IKK was important for AMPK regulation in LKB1-deficient cells, we asked whether IKK inhibition would further sensitize these cells to phenformin. IKK inhibition led to a decrease in AMPK Thr 172 phosphorylation in LKB1-deficient cells upon treatment with phenformin, which resulted in enhanced apoptosis. These results suggest that a combination of IKK inhibition and phenformin treatment could be a useful therapeutic strategy for LKB1-deficient cancers.
RESULTS

IKK is required for AMPK Thr 172 phosphorylation induced by IL-1
Two inducers of IKK activity, IL-1 and TNF, can increase AMPK Thr 172 phosphorylation in serum-starved HeLa cells, which lack LKB1, the major kinase that phosphorylates AMPK Thr 172 (17) . Because IL-1 is a potent inducer of IKK activity, we tested whether IKK is required for AMPK Thr 172 phosphorylation in response to IL-1. Pretreatment with the IKK-specific inhibitor Compound A (Bay 65-1942) (31) prevented IL-1 from inducing AMPK Thr 172 phosphorylation (Fig. 1A) . Phosphorylation of AMPK at Thr 172 mirrored the changes in the phosphorylation of IKK and amount of IB protein, which served as markers of IKK activity (Fig. 1A) . (20) . Compound A effectively inhibited IL-1-induced AMPK Thr 172 phosphorylation at 1 M ( fig. S1A) .
To validate the findings with Compound A, we expressed either wild-type (WT) or dominant-negative, kinase dead (KD; K44A) IKK in HeLa cells. IL-1 induced AMPK Thr 172 phosphorylation in cells expressing WT IKK but not in cells expressing KD IKK (Fig. 1B) . Knockdown of the essential IKK scaffold protein NEMO by small interfering RNA (siRNA) also blocked IL-1-induced AMPK Thr 172 phosphorylation in the LKB1-deficient A549 cells (Fig. 1C ). This finding indicated that the canonical IKK complex (which is defined by the presence of NEMO) was required for IL-1-induced AMPK Thr 172 phosphorylation. Because the previous data were all conducted in LKB1-deficient cells, we next tested whether the loss of LKB1 activity was required for IL-1 to induce IKK-dependent AMPK Thr 172 phosphorylation. WT mouse embryonic fibroblasts (WT MEFs) also showed an increase in AMPK Thr 172 in response to IL-1 that was blocked by deficiency in IKK (Fig. 1D) , an effect not seen in AMPK −/− MEFs (Fig. 1E ). IL-1 treatment for 30 min also induced ACC Ser 79 phosphorylation in A549 cells, an effect that was blocked by Compound A (Fig. 1F ).
An important consequence of AMPK activation is the induction of autophagy (34, 35) . IKK is involved in the induction of autophagy in response to rapamycin and nutrient deprivation (27) , and IKKmediated autophagy induction required AMPK, because knockdown of AMPK prevented constitutively active IKK from inducing autophagy (27) . IL-1 can induce autophagy in macrophage and epithelial cell lines (16, 36, 37) . IL-1 induces AMPK activity in LKB1-deficient A549 cells, and IL-1 increased the abundance of the autophagosome marker LC3-II (the more quickly migrating LC3 band) within 20 min of treatment in A549 cells (Fig. 1G) . Pretreatment with Compound A (Fig. 1H) or the AMPK inhibitor dorsomorphin ( fig. S1D) (38, 39) prevented LC3-II induction upon treatment with IL-1, indicating that IL-1-induced autophagosome formation required IKK and AMPK activity. The changes in LC3 mobility correlated with ACC Ser 79 phosphorylation, a marker of AMPK activity (Fig. 1F) . IL-1 also increased staining by a dye specific for acidified autophagosomes (Fig. 1I) . The increased autophagosome staining was blocked by Compound A, indicating that IKK and AMPK activity are required for IL-1 to induce autophagosome formation. Bafilomycin-A1, an inhibitor of autophagosome acidification (36) , also prevented IL-1-induced staining (Fig. 1I ). These findings indicated that the increased dye signal was due to increased autophagosome formation. These results were not due to direct off-target inhibition of AMPK by Compound A, because cell-free peptide-based assays showed that Compound A inhibited the kinase activity of recombinant IKK but not that of recombinant AMPK (figs. S1E and S2B). Together, the increase in phosphorylation of downstream AMPK targets and the increase in autophagosome formation in response to IL-1 indicate that the increased AMPK Thr 172 phosphorylation in response to IL-1 correlated with an increase in AMPK activity and promoted downstream signaling events. The abundance of autophagosomes was assayed using a commercially available kit. Cells were then stained with a dye that is selective for acidified autophagosomes, and total fluorescence intensity (TFI) was measured. Error bars represent the SEM of the average total fluorescence measured in three independent experiments.
(NIK) or MEKK3 (42) . In contrast to MEFs in which much of the basal AMPK Thr 172 phosphorylation depended on TAK1 (Fig. 2B) , basal AMPK Thr 172 phosphorylation in LKB1-deficient A549 cancer cells was independent of TAK1. Treatment of A549 cells with the TAK1 inhibitor NG-25 (43) or 5z-7-oxozeanol abolished phosphorylation of p38 (a marker of TAK1 pathway activation) (44) without affecting either AMPK Thr 172 phosphorylation or p65 Ser 536 phosphorylation (a marker of IKK activity; Fig. 2E ). These findings indicated that the majority of the basal IKK and AMPK activity in these cells was independent of TAK1. In A549 cells, Compound A treatment abolished the phosphorylation of p65 without affecting the ratio of phospho-p38 to total p38 (Fig. 2E) , indicating that TAK1 does not regulate basal AMPK or IKK activity in A549 cells and that IKK does not regulate basal TAK1 activity.
Canonical IKK regulates AMPK Thr 172 phosphorylation in cancer cell lines
The canonical IKK complex is a high-molecular weight complex containing the kinases IKK and IKK bound to the scaffold protein NEMO (23) . IKK is also found as a homodimer in the noncanonical IKK complex (25, 45 (Fig. 3D) . (Fig. 3E) . The rapid kinetics of inhibition of AMPK Thr 172 phosphorylation mediated by Compound A suggested the possibility that IKK directly regulates this phos phorylation site.
IKK regulates AMPK Thr
172 phosphorylation independently of changes in cellular energy status AMPK activity is tightly regulated by changes in the ratio of ADP/ ATP and AMP/ATP (5-7). An increase in the ratio of AMP/ATP or ADP/ATP is indicative of energetic stress and is generally associated with an increase in AMPK activity. Because IKK and NF-B also regulate cellular metabolism in certain contexts (47, 48) , we sought to determine whether IKK inhibition affected the ADP/ATP and AMP/ATP ratios. Compound A treatment increased both the ratios of AMP/ATP and ADP/ATP ( fig. S3A ), which indicates energetic stress and would be expected to increase AMPK Thr 172 phosphorylation in cells with LBK1 activity. However, at this time and concentration, Compound A decreased AMPK Thr 172 phosphorylation in A549 cells (Fig. 3E ). In addition, Compound A decreased Thr 172 phosphoryl ation on an AMPK kinase domain mutant that cannot bind to AMP ( fig.  S3B) (49) . These data indicate that the effects of Compound A on AMPK activity are independent of changes in ADP/ATP or AMP/ATP ratio.
IKK phosphorylates AMPK Thr
172 in cell-free kinase assays and induces its activity To determine whether IKK regulates AMPK through direct phosphorylation, we performed kinase assays using inactive recombinant AMPK trimers consisting of AMPK1, AMPK1, and AMPK1 (50) and glutathione S-transferase (GST)-IKK (1-786). AMPK1 incorporated  32 P-ATP when incubated with IKK ( fig. S4A) . To map the IKK-dependent phosphorylation sites on AMPK, we subjected a similar reaction performed with cold ATP to mass spectrometry (MS). Among the phosphopeptides identified was one that corresponded to phosphorylated Thr 172 ( fig. S4A ). Mutation of Thr 172 to alanine reduced incorporation of  32 P-ATP into AMPK1 in the presence of active IKK ( fig. S4B ). Western blotting confirmed that increasing amounts of IKK led to increased Thr 172 phosphorylation on AMPK trimers (Fig. 4A) .
Because phosphorylation of AMPK at Thr 172 increases the kinase activity of AMPK, we predicted that IKK would increase AMPK activity. As measured by the SAMS peptide kinase assay, AMPK activity was increased after incubation with IKK (Fig. 4B) . IKK also efficiently phosphorylated a KD mutant of AMPK (Fig. 4C) , indicating that the IKK effect on AMPK Thr 172 was independent of AMPK autocatalytic activity. We next compared the relative efficacy of IKK and IKK relative to AMPK Thr 172 phosphorylation. IKK phosphorylated about fivefold more AMPK Thr 172 than IKK in cell-free kinase assays (Fig. 4D) . Moreover, IKK bound more effectively to the AMPK kinase domain than did IKK, as evidenced by coprecipitation experiments in which a GST-tagged AMPK kinase domain was precipitated from HEK293T cells (Fig. 4E) . These findings suggested that IKK was the dominant kinase for AMPK Thr 172 within the canonical IKK complex. Compound A effectively inhibited IKK-mediated AMPK Thr 172 phosphorylation but did not prevent either TAK1 or CAMKK2 (two other upstream AMPK kinases) from phosphorylating AMPK Thr 172 (Fig. 4F) . Thus, the effect of Compound A on AMPK Thr 172 phosphorylation in cells is independent of inhibition of either TAK1 or CAMKK2.
IKK inhibition leads to reduced AMPK Thr
phosphorylation in phenformin-treated LKB1-deficient cells and promotes apoptosis
Phenformin is an inhibitor of complex I of the mitochondria (51-53) and leads to ATP depletion (29) . To counteract the action of phenformin, AMPK is activated to conserve ATP (30) . Phenformin-induced AMPK activity depends largely on the upstream AMPK-activating kinase LKB1, and LKB1-deficient cancer cell lines are particularly sensitive to phenformin-induced apoptosis, as measured by caspase 3/7 activation (29, 30) . Because IKK regulated AMPK in LKB1-deficient cells and IKK-mediated AMPK regulation was independent of energy status ( fig. S1C ), we asked whether IKK inhibition would further sensitize these cells to phenformin-induced apoptosis. We transfected A549 (LKB1-deficient) and MDA-MB-231 (LKB1-positive) cells with siRNA-targeting NEMO to inhibit IKK. Both A549 and MDA-MB-231 cells had lower basal AMPK Thr 172 phosphorylation when NEMO was knocked down (Figs. 3A and 5A ). Phenformin treatment induced AMPK Thr 172 phosphorylation only in MDA-MB-231 cells, and this effect did not change in cells with NEMO knockdown (Fig. 5A) . Accordingly, NEMO knockdown led to phenformin-induced apoptosis as measured by caspase 3/7 activity in A549 cells. In contrast, NEMO knockdown did not alter caspase 3/7 induction by phenformin in MDA-MB-231 cells (Fig. 5B) . Similarly, Compound A treatment in combination with phenformin decreased AMPK Thr 172 phosphorylation in A549 cells but not in MDA-MB-231 (Fig. 5C ). This finding was consistent with previous work indicating that LKB1 is required for phenformin to induce AMPK Thr 172 phosphorylation. These data also suggested that IKK is not required for phenformin-induced AMPK activation, consistent with our previous findings that IKK regulates AMPK independent of cellular metabolic changes.
We next tested the effects of Compound A, phenformin, or the combination of the two drugs in a panel of LKB1-deficient (HeLa, A549, NCI-H23, and NCI-H460) or LKB1-positive cell lines (IMR90, NCI-H441, MDA-MB-231, and MiaPaca-2). One millimolar phenformin was used because this concentration was sufficient to induce AMPK Thr 172 in LKB1-expressing cells but did not induce measurable apoptosis in LKB1-deficient cells 18 hours after treatment as measured by caspase 3/7 activity. On average, the combination of phenformin and Compound A induced more caspase 3/7 activity in LKB1-deficient cells than in LKB1-expressing cells (Fig. 5D) . Together, these results indicate that IKK inhibition sensitizes LKB1-deficient cells to phenformin-induced apoptosis by decreasing AMPK Thr 172 phosphorylation. Overexpression of TAK1 and the adaptor protein TAB1 is sufficient to promote AMPK phosphorylation. Moreover, TAK1/TAB1 fusion proteins can directly phosphorylate AMPK Thr 172 in cell-free kinase assays (16, 17, 54) . However, TAK1 is not active in vitro unless the adaptor protein TAB1 is also present and thus cannot phosphorylate AMPK in the absence of recombinant TAB1 (54) . Stimuli such as IL-1, TNF-, and TRAIL that activate TAK1 lead to the induction of AMPK activity (16, 17, 54) . Here, we provided evidence ( Fig. 2A) that inhibition of TAK1 prevented these stimuli from inducing AMPK Thr 172 phosphorylation. Collectively, these data suggest that cytokineinduced TAK1 activity leads to direct phosphorylation of AMPK Thr 172 by TAK1. Expression of a constitutively active IKK mutant that mimics TAK1 phosphorylation leads to an increase in AMPK Thr 172 phosphorylation in HeLa cells, which are LKB1-deficient (27) . This result suggested a potential role for IKK downstream of TAK1 in regulating AMPK. Here, we demonstrated that IKK activated AMPK downstream of TAK1 in response to IL-1 or TNF-.
DISCUSSION
The canonical IKK complex, which is defined by the presence of the scaffolding protein NEMO (25) , promoted AMPK activity in response to IL-1 and TNF- (Figs. 1, A to F, and 2A) . In addition to NEMO, the canonical IKK complex consists of two related protein kinases, IKK and IKK, which show variable activity toward different substrates in the NF-B pathway. For example, IKK has higher activity toward IB than IKK, but IKK has a higher activity toward p100 than IKK (55) . With respect to AMPK, IKK had a fivefold greater activity toward AMPK Thr 172 than IKK (Fig. 4D ). This could be because IKK shows more kinase activity toward AMPK Thr 172 or because IKK is directed to and binds AMPK more efficiently than IKK, as was observed with GST pulldowns in HEK293T cells (Fig. 4E) . These findings suggested that it was IKK within the canonical complex that directly phosphorylated AMPK Thr Caspase 3/7 activity of each cell line was measured. The average of three independent experiments is shown in the graph (a two-way ANOVA was performed to determine which groups were statistically different). **P < 0.01.
that specifically activate the noncanonical IKK complex promote activation of AMPK. Although IKK showed less activity toward AMPK Thr 172 than IKK, it is still possible that a stimulus that specifically stimulates IKK could promote AMPK activity.
The IKK/NF-B pathway promotes its own feedback to limit the response to IL-1 and TNF-, notably by inducing the transcription of IB (56) . Activation of AMPK may be another way to limit NF-B signaling in response to these cytokines, indicated by several studies (57, 58) . TNF--induced apoptosis is opposed by AMPK (59), which is in line with the role of IKK in promoting survival over apoptosis in response to TNF-. Consistent with the idea that IL-1 induces AMPK in an IKK-dependent fashion, IL-1 promoted autophagosome formation in an IKK-dependent manner in A549 cells, which lack LKB1. IL-1 also promotes autophagy in breast epithelial cells (16) and in macrophages (37) , which both express LKB1. IKK is involved in autophagy induction (22) by promoting the transcription of autophagic genes (28) and the formation of autophagosomes in response to several autophagy-inducing stimuli. Knockdown of AMPK prevented the induction of autophagosomes by overexpression of constitutively active IKK, suggesting that AMPK is downstream of IKK with respect to autophagy (27) , specifically, through the direct phosphorylation of AMPK Thr 172 by IKK. We also demonstrated that IKK regulated basal AMPK activity independently of TAK1, because inhibition of IKK in TAK1 −/− MEFs led to a decrease in AMPK Thr 172 phosphorylation. In addition to TAK1-mediated phosphorylation, IKK can also be activated by transautophosphorylation, which is induced by forced proximity in the presence of linear ubiquitin molecules (24), or another upstream signal, such as from MEKK3 or NIK (42) . Regardless of the source of the residual IKK activity, inhibiting IKK lowered basal AMPK Thr 172 phosphorylation in the absence of TAK1 activity (Fig. 2, C and D) . This effect was similar to how basal IKK activity in A549 cells was independent of TAK1 activity (Fig. 3E) .
The loss of LKB1 in cancer not only promotes tumor growth but also leaves the cells vulnerable to metabolic stress, such as with treatment with the mitochondrial complex I inhibitor phenformin (29, 30) . However, little progress has been made in the clinic toward exploiting this vulnerability. This could be because LKB1-deficient cancer cells promote basal AMPK phosphorylation through IKK to buffer against energetic stress. Here, we demonstrated that IKK inhibition in LKB1-deficient cells led to decreased phosphorylation of AMPK Thr 172 , even when the cells were treated with phenformin (Fig. 5, A  and B ). This decrease in AMPK Thr 172 phosphorylation was associated with apoptosis, as measured by caspase 3/7 activity (Fig. 5, C and  D) . In cells with LKB1, IKK did not affect the ability of phenformin to induce AMPK Thr 172 phosphorylation. Phenformin alone or in combination with IKK inhibition did not induce apoptosis in cells with LKB1. A future therapeutic strategy might be to combine IKK inhibition with phenformin treatment in LKB1-deficient tumors.
MATERIALS AND METHODS
Cell culture
All cell lines were obtained from the Lineberger Comprehensive Cancer Center Tissue Culture Facility and cultured in DMEM (Gibco) or RPMI 1640 (Gico), depending on American Type Culture Collection recommendations, supplemented with 10% FBS (Sigma), penicillin (100 U/ml), streptomycin (100 g/ml; Gibco), and 1 mM glutamine. Immortalized MEFs of the indicated genotypes were described previously (28) . All cell lines were maintained in a humidified incubator at 37°C and 5% CO 2 .
Antibodies and compounds
All antibodies were purchased from Cell Signaling Technology. Compound A (Bay65-1942) and Compound B (both provided by Bayer) were dissolved in DMSO. The TAK1 inhibitor 5z-7-oxozeanol and the AMPK inhibitor dorsomorphin were purchased from Tocris Biosciences, and NG-25 was purchased from MedChem Express. Phenformin hydrochloride was purchased from Sigma-Aldrich. Recombinant IL-1 was purchased from Peprotech, and recombinant TNF- was purchased from Promega. The NBD peptide was synthesized by American Peptide.
siRNA transfections ON-TARGETplus SMARTpool siRNA or individual siRNAs (all siRNAS were pooled unless otherwise indicated) and a negative control siRNA were purchased from Dharmacon (Thermo Scientific Pierce). Each pool was reconstituted in 1× siRNA buffer (Dharmacon) and diluted in diethyl pyrocarbonate-treated water to a final concentration of 20 M. Briefly, 1.5 × 10 5 cells were plated onto 10-cm dishes and cultured as described above. The following day, Dharmacon transfection reagent #1 (Thermo Scientific) and 200 pmol of siRNA mixture were incubated for 20 min at room temperature and added to the cells in serum-free media. Cells were harvested 48 to 72 hours after transfection for protein extraction preparation.
Plasmid transfections
Plasmids were transfected using the X-tremeGENE Transfection Reagent (Roche Life Science) according to the manufacturer's protocol. Mutations were confirmed by Sanger sequencing at the University of North Carolina (UNC) Genome Analysis Core. The AMPK kinase domain pEBG-AMPK1(1-312) (Addgene plasmid #27632). KD AMPK 1 to 312 was created by mutating D157 to A in pEBG-AMPK1(1-312) using a quick-change mutagenesis protocol. AMPK T172A was created by cloning pDONR223-AMPK1 (Addgene plasmid #82274) into the pDEST-27 to add a GST tag using Gateway Cloning (Invitrogen). Thr 172 was then mutated to alanine using a quick-change mutagenesis protocol. The WT and KD mutant (K44A) IKK, as well as the TAK1 and TAB1 plasmids, were gifts from L. Cantley (Meyer Cancer Center, Weill Cornell Medical College).
Kinase assays
Kinase assays were performed as described previously (60) . For the kinase assays using recombinant proteins, AMPK trimers purified from Escherichia coli were used as previously described (50) (a gift from J. Brenman, UNC Chapel Hill). Purified GST-tagged IKK and IKK from Sf9 insect cells were obtained from SignalChem. The kinase buffer contained 1 mM -glycerolphosphate, 20 mM tris (pH 7.4), 12 mM MgCl 2 , and 100 M cold ATP.  32 P-ATP was added where indicated. The reactions were then subjected to SDS-polyacrylamide gel electrophoresis (PAGE) and either transferred to a nitrocellulose membrane for Western blotting (see below) or Coomassie-stained for MS. The MS experiments were performed with the UNC Proteomics Core Facility. The band corresponding to the AMPK1 subunit was excised from the gel and digested with trypsin. Phosphopeptides were enriched using titanium dioxide and then subjected to liquid chromatography-MS (LC-MS) using an LTQ Orbitrap Velos (Thermo Scientific) ion trap mass spectrometer. Peptides were identified using Mascot Software. For the SAMS peptides assays (61), the resulting kinase reactions were mixed with SAMS peptide for 15 min and then spotted on squares of p81 phosphocellulose paper. Each square was washed three times in 1% phosphoric acid and then dried, and the remaining radioactivity was measured using a scintillation counter. To determine the effect of Compound A on AMPK1 or IKK activity, peptide-based kinase assays were performed as described previously, using 100 M ATP and 5 M Compound A (62) . Active AMPK1, AMPK1, or AMPK1, as well as the SAMS peptide and the IB peptide were obtained from Medical Research College Protein Phosphorylation and Ubiquitylation Unit Reagents and Services facility [MRC PPU, College of Life Sciences, University of Dundee, Scotland (https:// mrcppureagents.dundee.ac.uk)].
Western blotting
Whole-cell protein extraction was performed by scraping the cells in cold 1% NP-40 buffer [20 mM tris (pH 7.6), 1 mM EDTA, 1 mM EGTA, 150 mM NaCl, and 1% Igepal]. Protein concentrations were determined using the Bradford Assay (Bio-Rad). Protein lysates were resolved by SDS-PAGE, transferred to nitrocellulose membranes (GE Healthcare Life Sciences), blocked for 1 hour in 1× TBST (trisbuffered saline 1% Tween) containing 5% nonfat milk, and incubated overnight in corresponding primary antibody at 4°C. Blots were then incubated with horseradish peroxidase-labeled secondary antibody and developed using Amersham ECL Prime Western Blotting Detection Reagent (GE Healthcare Life Sciences), or the Bio-Rad ChemiDoc system. Densitometry of the relevant bands was performed using ImageJ, and the values were normalized to either total protein or actin as indicated in the figures. The data from independent biological replicates were then plotted using GraphPad Prism. For statistical analysis, a two-way ANOVA followed by a Bonferroni post test was performed to determine statistical significance.
GST pulldowns
Whole-cell extracts were prepared in 1% NP-40 buffer, and 5% of the extract was saved for use as input. The rest was allowed to rotate overnight at 4°C with glutathione-conjugated beads (Amersham, GE Healthcare Life Sciences). The following day, the beads were centrifuged and washed three times in 1% NP-40 buffer. Proteins were eluted from the beads by boiling in Laemmeli buffer and then subjected to SDS-PAGE and Western blotting.
Measurement of ADP/ATP and AMP/ATP ratios A549 cells were treated with either DMSO or Compound A (5 M) for 30 min. The ratio of ADP/ATP and AMP/ATP was then measured at the UNC Biomarker Mass Spectrometry Core Facility using a protocol similar to that described by Johnsen et al. (63) . Known amounts of stable isotopes of ATP, ADP, and AMP (purchased from MilliporeSigma) were added to each sample, the samples were subjected to high-performance LC (HPLC) using a Surveyor HPLC system and then analyzed on a Thermo Fisher TSQ-Quantum Ultra triple-quadrupole mass spectrometer.
Autophagosome stain
The autophagosome-specific stain was purchased from Sigma-Aldrich (catalog #MAK-138). Cells were seeded at a density of 1000 cells per well of a 96-well dish. The following day, the cells were left untreated, treated with IL-1, or treated with IL-1 in combination with Compound A or bafilomycin. Cells were then washed four times in the wash buffer provided with the detection kit, and then, the total fluorescence intensity was measured using a 96-well plate reader. The excitation and emission were 360 and 520 nm, respectively.
Caspase assays
The Caspase-Glo reagent was purchased from Promega and used according to the manufacturer's instructions. Cells were seeded at a density of 1000 cells per cell of a white-walled 96-well plate. The Caspase-Glo reagent was then directly added to the wells and placed on a shaker at room temperature for 30 min, and then, the luminescence was read using a plate reader.
SUPPLEMENTARY MATERIALS
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